MS and Demyelinating Disorders

The treatment, marketed as Uplizna, is only the second approved therapy for NMOSD.

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.

The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

After respective approvals in December 2019 and March 2020, lemborexant (Dayvigo; Eisai) and ozanimod (Zeposia; Bristol Myers Squibb) have become available for patients with insomnia and multiple sclerosis.

The clinical healthy psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the reasoning behind his study evaluating conformity of masculine norms in patients with multiple sclerosis.

Neurology News Network for the week ending June 6, 2020.

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The anti-CD20 monoclonal antibody had an original PDUFA date of June 2020.

The vice president of Global Program Leadership in Neurology and Immunology at EMD Serono discussed the recent long-term phase 2 data on evobrutinib presented at CMSC 2020.

Neurology News Network for the week ending May 30, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

Following the 2020 Consortium of Multiple Sclerosis Centers Virtual Annual Meeting, the organization has scheduled a mini poster session and product theaters for June 1-14.

Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.